Lantern Pharma (LTRN)
Develops oncology candidates using data science and biomarker-guided drug development.
Something off on this page? Send us feedback.
Develops cancer drug candidates with RADR®, a platform that links genomic signatures to drug response. Its clinical portfolio combines three lead candidates with an antibody-drug-conjugate program, and revenue depends on regulatory approval or possible licence and grant income.
RADR® applies big-data analytics, genomics, machine learning and artificial intelligence to identify genomic signatures associated with drug response. The platform supports selection, rescue and repositioning of cancer drug candidates alongside biomarker-driven development of new compounds.
The clinical portfolio includes LP-300, LP-184 and LP-284, plus an antibody-drug-conjugate program across cancer indications. Operations are based in Texas, with subsidiaries in the United Kingdom and Australia.
Commercial outcomes depend on advancing candidates through clinical development and gaining regulatory approval. The company expects operating losses and no product revenue before approvals, apart from possible licence and grant revenue.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $7.4M · Total debt $39.7K · Total assets $8.6M · Shareholders' equity −$3.2M
- Revenue
- $0
- Operating income
- −$3.5M
- Net income
- −$7.1M
No dividends on record.
| Institutions33 holders · as of Mar 31, 2026 | 16.40% | 2.10M shares | |
| Insiders6 holders · as of May 14, 2026 | 22.73% | 2.91M shares | |
| Otherremainder | 60.87% | 7.78M shares |
12.78M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Empery Asset Management, LPInstitution | 10.35% | 1.32M | 13Gfiled Aug 4, 2026 ↗ |
Aaron G.L. FletcherInsider10 percent owner | 8.21% | 1.05M | Form 4filed Jun 13, 2025 ↗ |
Bios Capital Management, LPInstitution | 6.76% | 864,435 | 13Fas of Mar 31, 2026 |
of 17 PagesInsider | 5.26% | 672,758 | 13Gfiled Feb 16, 2021 ↗ |
Thomas A. Satterfield, Jr.Insider | 4.46% | 570,000 | 13Gfiled Apr 3, 2026 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 12, 2026 | D. Jeffrey Keyser | director | +97,088 | $2.17 |
| May 12, 2026 | Lee Troy Schalop | director | +97,088 | $2.17 |
- AstraZeneca (ADR)
EGFR-mutated NSCLC franchise built around Tagrisso
- Gilead Sciences
Trop-2 ADC approved for first-line metastatic TNBC
- Bristol-Myers Squibb
Commercialized cell therapy for relapsed or refractory B-cell lymphomas
- ADC Therapeutics
Commercial-stage developer of the CD19 ADC ZYNLONTA for r/r DLBCL
- Karyopharm Therapeutics
Oral XPO1 inhibitor marketed for relapsed/refractory DLBCL
- Kazia Therapeutics (ADR)
Brain-penetrant PI3K/mTOR program for glioblastoma and other CNS tumors
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Lantern Pharma | $1.94 | +0.52% | $24.6M | — | — | — | — |
| AstraZeneca (ADR) | $163.48 | +1.13% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Gilead Sciences | $149.20 | −0.27% | $185.75B | — | 16.5 | 6.1 | +10.2% |
| Bristol-Myers Squibb | $67.65 | −0.01% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| ADC Therapeutics | $1.31 | −1.13% | $167.9M | — | — | 2.1 | +2.2% |
| Karyopharm Therapeutics | $1.80 | +1.12% | $40.6M | — | — | 0.3 | −11.9% |
| Kazia Therapeutics (ADR) | $13.35 | +4.87% | $20.4M | — | — | 1,444.7 | — |
| Median | 19.6 | 15.2 | 3.5 | +5.7% |